3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
Modify Date: 2022-11-09 11:44:14
![3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide Structure](https://www.chemsrc.com/caspic/112/193012-35-0.png)
3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide structure
|
Common Name | 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide | ||
|---|---|---|---|---|
| CAS Number | 193012-35-0 | Molecular Weight | 468.39700 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H23Cl2N3O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamideFK614 is an orally active, potent, selective PPARγ modulator (SPPARM). FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is a nonthiazolidinedione insulin sensitizer. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes[1][2][3]. |
| Name | 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | FK614 is an orally active, potent, selective PPARγ modulator (SPPARM). FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is a nonthiazolidinedione insulin sensitizer. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
PPAR-γ |
| In Vitro | FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia[1][2]. |
| In Vivo | FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level[3]. FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance[3]. Animal Model: db/db Mice Dosage: 0.1~10 mg/kg Administration: P.o. Result: Improved the impaired glucose tolerance. Animal Model: db/db Mice Dosage: 0.32~3.2 mg/kg Administration: P.o. Result: Dose-dependently reduced plasma glucose level. |
| References |
| Molecular Formula | C21H23Cl2N3O3S |
|---|---|
| Molecular Weight | 468.39700 |
| Exact Mass | 467.08400 |
| PSA | 92.93000 |
| LogP | 6.60520 |
| 1-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-1H-benzimidazole-6-carboxamide |
| 1-(2,4-dichlorobenzyl)-2-methyl-6-(1-pentanesulfonylcarbamoyl)benzimidazole |
| 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide |
| FK614 |